Tumor lysis syndrome

💡 What You Need to Know

Definition: Tumor lysis syndrome (TLS) is a life-threatening oncologic emergency caused by the rapid breakdown of malignant cells, releasing intracellular contents into the bloodstream.
Causes: Most commonly triggered by cytotoxic chemotherapy, but can also occur spontaneously or with radiation therapy, hormonal therapy, or biological agents, especially in highly proliferative cancers like leukemia.
High-Risk Patients: Individuals with high tumor burden, rapidly proliferating cancers (e.g., acute leukemias, high-grade lymphomas), pre-existing renal dysfunction, dehydration, or elevated baseline uric acid levels are at increased risk.
Metabolic Disturbances: Characterized by hyperkalemia, hyperphosphatemia, hypocalcemia, and hyperuricemia, leading to potential acute kidney injury and cardiac arrhythmias.

🤒 Associated Symptoms

Hyperkalemia: May manifest as muscle weakness, paresthesias, fatigue, and potentially life-threatening cardiac arrhythmias (palpitations, irregular heartbeat).
Hyperphosphatemia: Can cause nausea, vomiting, diarrhea, lethargy, and contribute to renal dysfunction through calcium-phosphate precipitation.
Hypocalcemia: Often asymptomatic but can lead to muscle cramps, tetany, perioral numbness, Chvostek's or Trousseau's signs, and in severe cases, seizures or cardiac dysfunction.
Hyperuricemia: May present with nausea, vomiting, flank pain (due to uric acid nephropathy), oliguria, and symptoms of acute kidney injury.
Acute Kidney Injury (AKI): Decreased urine output, edema, fatigue, and general malaise due to impaired renal function.

🛡 Crucial Precautions

Prophylactic Hydration: Initiate aggressive intravenous hydration (e.g., 2-3 L/m²/day) 24-48 hours before and during cytotoxic therapy to maintain high urine output and prevent uric acid precipitation.
Uric Acid Reduction: Administer allopurinol or rasburicase as prophylaxis based on TLS risk stratification to reduce uric acid levels.
Electrolyte Monitoring: Perform frequent monitoring of serum electrolytes (potassium, phosphate, calcium), uric acid, creatinine, and BUN, especially during the first 72 hours post-treatment.
Cardiac Monitoring: Consider continuous ECG monitoring for high-risk patients or those with hyperkalemia to detect arrhythmias.
Avoid Nephrotoxic Agents: Minimize or avoid medications that can impair renal function (e.g., NSAIDs, certain antibiotics) during the high-risk period.

🍽 Dietary Directions & Restrictions

Aggressive Hydration: Encourage consistent oral fluid intake in addition to prescribed intravenous fluids, unless contraindicated by fluid overload risk.
Potassium Restriction: If hyperkalemia is present or anticipated, restrict high-potassium foods (e.g., bananas, oranges, potatoes, leafy greens) and avoid potassium-containing intravenous fluids.
Phosphate Restriction: In cases of hyperphosphatemia, limit foods rich in phosphorus (e.g., dairy products, nuts, processed foods).
Fluid Balance Monitoring: Maintain strict intake and output records to ensure adequate hydration and identify signs of fluid retention or dehydration.
Avoid Alcohol and Caffeine: These can contribute to dehydration and should be limited or avoided during the high-risk period.

⚠️ Attendant Guidelines

Recognize Early Signs: Caregivers should be educated on recognizing early symptoms of TLS, such as muscle cramps, fatigue, decreased urination, or irregular heartbeat, and report them immediately.
Adherence to Hydration: Ensure the patient strictly adheres to prescribed oral and intravenous fluid regimens to prevent dehydration and promote renal clearance.
Medication Compliance: Administer all prescribed medications, especially allopurinol or rasburicase, exactly as directed to prevent or manage metabolic imbalances.
Monitor Urine Output: Closely monitor and record urine output, reporting any significant decrease to the healthcare team promptly.
Emergency Preparedness: Understand when to seek immediate medical attention for severe symptoms like seizures, severe muscle weakness, or significant changes in consciousness.

🩺 Physician's Perspective

Risk Stratification: Assess each patient's risk for TLS (low, intermediate, high) based on tumor type, burden, baseline lab values, and renal function to guide prophylactic strategies.
Diagnostic Criteria: Utilize Cairo-Bishop criteria for laboratory and clinical TLS diagnosis, focusing on changes in uric acid, potassium, phosphate, and calcium levels.
Prophylaxis vs. Treatment: Implement aggressive prophylactic measures for high-risk patients, including hydration and uric acid-lowering agents (allopurinol for prevention, rasburicase for established hyperuricemia or high-risk prophylaxis).
Electrolyte Management: Actively manage electrolyte imbalances with specific interventions: calcium gluconate for symptomatic hypocalcemia, insulin/glucose or sodium polystyrene sulfonate for hyperkalemia, and phosphate binders for hyperphosphatemia.
Renal Support: Be prepared for renal replacement therapy (dialysis) in cases of severe, refractory electrolyte imbalances or acute kidney injury.

🎓 Academic & Nursing Corner

Comprehensive Assessment: Perform frequent vital sign monitoring, neurological assessments, and assess for signs of fluid overload or dehydration.
Fluid Management: Accurately administer prescribed IV fluids and monitor strict intake and output, reporting any discrepancies or changes in urine output.
Medication Administration: Administer allopurinol, rasburicase, and electrolyte replacement therapies as ordered, understanding their mechanisms of action and potential side effects.
Laboratory Monitoring: Be vigilant in reviewing and reporting critical laboratory values (e.g., hyperkalemia, hypocalcemia, elevated uric acid, creatinine) to the medical team promptly.
Patient and Family Education: Educate patients and their families about TLS, the importance of hydration, medication adherence, and when to report symptoms.
Cardiac Monitoring: Set up and monitor continuous ECG for patients at risk of cardiac arrhythmias due to electrolyte imbalances.

🔬 Clinical Reference Index

Key Terms: Hyperkalemia, Hyperphosphatemia, Hypocalcemia, Hyperuricemia, Acute Kidney Injury (AKI), Uric Acid Nephropathy, Cairo-Bishop Criteria.
Diagnostic Tests: Serum electrolytes (K+, PO43-, Ca2+), Uric Acid, Creatinine, Blood Urea Nitrogen (BUN), Lactate Dehydrogenase (LDH), Electrocardiogram (ECG).
Pharmacological Agents: Allopurinol (xanthine oxidase inhibitor), Rasburicase (recombinant urate oxidase), Sodium Bicarbonate, Calcium Gluconate, Insulin/Glucose, Sodium Polystyrene Sulfonate (Kayexalate), Phosphate Binders.
Management Strategies: Aggressive intravenous hydration, Diuretics (loop diuretics if fluid overload), Renal Replacement Therapy (Hemodialysis, CRRT).
Risk Factors: High tumor burden, high proliferative rate, pre-existing renal insufficiency, dehydration, specific chemotherapy agents.

Disclaimer: This clinical infographic is generated for informational, educational, and general awareness purposes only. It does not constitute formal medical advice, definitive diagnosis, or a recommended treatment protocol. The clinical guidelines presented herein should not be used as a substitute for professional medical consultations, clinical examinations, or the direct advice of a certified healthcare practitioner. Always seek the immediate advice of your primary care physician or other qualified medical specialists regarding any health conditions or emergent symptoms.